First-in-class small molecule ONC201 induces DR5 and cell death in tumor but not normal cells to provide a wide therapeutic index as an anti-cancer agent

PLoS ONE

Volumn 10, Issue 11, 2015, Pages

  Allen, Joshua E ^a   Crowder, Roslyn ^b   El Deiry, Wafik S ^c  

^a Oncoceutics   (United States)

^b STETSON UNIVERSITY   (United States)

^c FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEATH RECEPTOR 5; DOXORUBICIN; ONC 201; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; FUSED HETEROCYCLIC RINGS; TIC10 COMPOUND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BEAGLE; CELL DEATH; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LOW DRUG DOSE; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; NONHUMAN; RAT; SINGLE DRUG DOSE; SPECIES COMPARISON; THERAPEUTIC INDEX; TOXICITY TESTING; TOXICOKINETICS; AGONISTS; ANIMAL; ANTIBODY SPECIFICITY; CELL CYCLE; CELL LINE; CLINICAL TRIAL (TOPIC); DOG; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; LD50; METABOLISM; SIGNAL TRANSDUCTION; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; LETHAL DOSE 50; MALE; ORGAN SPECIFICITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION;

EID: 84957883015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143082     Document Type: Article

References (17)

1. Allen JE, Krigsfeld G, Mayes PA, Patel L, Dicker DT, Patel AS, et al. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects. Science translational medicine. 2013; 5(171):171ra17. doi: 10.1126/scitranslmed.3004828 PMID: 23390247.
2. Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology. 2009; 127(2):145-54. doi: 10.1111/j.1365-2567.2009.03058.x PMID: 19476510; PubMed Central PMCID: PMC2691779.
3. Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Cancer biology & therapy. 2012; 13 (12):1143-51. doi: 10.4161/cbt.21354 PMID: 22892844; PubMed Central PMCID: PMC3469471.
4. Plenderleith IH. Treating the treatment: Toxicity of cancer chemotherapy. Canadian family physician Medecin de famille canadien. 1990; 36:1827-30. PMID: 21234006; PubMed Central PMCID: PMC2280515.
5. Liu S, Kurzrock R. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer treatment reviews. 2014; 40(7):883-91. doi: 10.1016/j.ctrv.2014.05.003 PMID: 24867380.
6. Mohile SG, Klepin HD, Rao AV. Considerations and controversies in the management of older patients with advanced cancer. American Society of Clinical Oncology educational book / ASCO American Society of Clinical Oncology Meeting. 2012:321-8. doi: 10.14694/EdBook-AM.2012.32.321 PMID: 24451757.
7. Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, et al. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget. 2014; 5(24):12728-37. PMID: 25587031.
8. Wu GS, Burns TF, McDonald ER 3rd, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage- inducible p53-regulated death receptor gene. Nature genetics. 1997; 17(2):141-3. doi: 10.1038/ ng1097-141 PMID: 9326928.
9. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, et al. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer biology & therapy. 2008; 7(12):2034-8. PMID: 19106633.
10. Allen JE, Prabhu VV, Talekar M, van den Heuvel AP, Lim B, Dicker DT, et al. Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10. Cancer research. 2015; 75(8):1668-74. doi: 10.1158/0008-5472.CAN-14-2356 PMID: 25681273.
11. Talekar MK, Allen JE, Dicker DT, El-Deiry WS. ONC201 Induces Cell Death in Pediatric non-Hodgkin's Lymphoma Cells. Cell cycle. 2015:0. doi: 10.1080/15384101.2015.1054086 PMID: 26030065.
12. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. The Journal of clinical investigation. 1999; 104(2):155-62. doi: 10. 1172/JCI6926 PMID: 10411544; PubMed Central PMCID: PMC408479.
13. Yamaguchi H, Wang HG. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. The Journal of biological chemistry. 2004; 279 (44):45495-502. doi: 10.1074/jbc.M406933200 PMID: 15322075.
14. Ishizawa J, Kojima K, Chachad D, Ruvolo PP, Ruvolo VR, Jacamo R, et al. ONC201 Induces p53-Independent Apoptosis and Cell Cycle Arrest in Hematological Malignancies and Leukemic Stem/Progenitor Cells By Inducing ER Stress and mTOR Inhibition2014 2014-12-06 00:00:00. 3122- p.
15. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R. Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor. Proceedings of the National Academy of Sciences of the United States of America. 2003; 100(11):6523-8. doi: 10.1073/pnas.0731871100 PMID: 12750477; PubMed Central PMCID: PMC164479.
16. Lu M, Lawrence DA, Marsters S, Acosta-Alvear D, Kimmig P, Mendez AS, et al. Cell death. Opposing unfolded-protein-response signals converge on death receptor 5 to control apoptosis. Science. 2014; 345(6192):98-101. PubMed Central PMCID: PMC4284148.
17. Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small-Molecule ONC201/TIC10 Targets Chemotherapy- Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner. Cancer research. 2015; 75(7):1423-32. doi: 10.1158/0008-5472.CAN-13-3451 PMID: 25712124.